Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

222.32 -2.30 (-1.02%)
Streaming Delayed Price Updated: 2:17 PM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson? ↗
They have combined for 118 years of consecutive dividend increases. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy? ↗
It's hard to argue against its reliability. 
Via The Motley Fool
News headline image
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
From Johnson & Johnson
Via Business Wire
Johnson & Johnson (NYSE:JNJ) Screens Well as a Dependable Dividend Aristocrat ↗
Via Chartmill
News headline image
Are Wall Street Analysts Bullish on Johnson & Johnson Stock?
Johnson & Johnson has outperformed the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
The Best Dividend Stocks to Buy and Hold Forever ↗
These companies are built to last. And their stocks are built for owning over the long term. 
Via The Motley Fool
News headline image
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? ↗
These longtime market beaters may not have peaked yet. 
Via The Motley Fool
Topics World Trade
News headline image
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
From Johnson & Johnson
Via Business Wire
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
These companies are leaders in their fields. 
Via The Motley Fool
News headline image
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference
From Johnson & Johnson
Via Business Wire
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Small Cap or Megacap: Which Healthcare Stock Is Right for You? ↗
Healthcare companies with different market caps offer different rewards and challenges. 
Via The Motley Fool
Top gainers and losers in the S&P500 index during Wednesday's after-hours session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Founders Capital Loads Up on Midstream Stock With $3.4 Million Buy, According to Recent SEC Filing ↗
Plains GP Holdings runs a major North American network for crude oil and NGL transport and storage, serving producers and refiners. 
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
From Johnson & Johnson
Via Business Wire
News headline image
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4% ↗
Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025. 
Via MarketBeat
News headline image
Could This Healthcare Stock Help Make You Rich Over the Next Decade? ↗
Intuitive Surgical has already made many of its early investors wealthy. 
Via The Motley Fool
News headline image
Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report? ↗
Solid results weren't impressive enough to move the stock price higher. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
This once-beaten-down pharma stock remains an intriguing turnaround story. 
Via The Motley Fool
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
These companies boast significant upside potential. 
Via The Motley Fool
News headline image
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine ↗
The blue chip dividend stock is quietly growing again as a streamlined company. 
Via The Motley Fool
News headline image
3 Healthcare Stocks That Have Held Up in Every Market Downturn ↗
Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns. 
Via The Motley Fool
Topics Economy
News headline image
Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now ↗
Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation 
Via MarketBeat
Topics Bonds Earnings Economy
News headline image
The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson ↗
MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data. 
Via Benzinga
News headline image
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results ↗
Johnson & Johnson (NYSE:JNJ) reports upbeat earnings for Q1, with higher sales and raised fiscal 2026 guidance. Some analysts raise price targets. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.